Showing results (61-70 of 1,877) with videos related to

Sort By:
Pageof 188
Immunotherapy|February 8, 2019
Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysisHazem El-Osta, Syed Jafri
Immunotherapy|February 8, 2019
Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case seriesDaniel Jiahao Wong, Joycelyn Lee, Su Pin Choo, et al.
Immunotherapy|February 8, 2019
Early fatal hemoptysis after first-dose, first-line pembrolizumab in a central lung cancer: did tumor shrinkage matter?Francesco Facchinetti, Maria Majori, Mariangela Sabato, et al.
Immunotherapy|December 10, 2019
Cardiac tamponade in a patient with stage IV lung adenocarcinoma treated with pembrolizumabAbdul Moiz Khan, Ayesha Munir, Vimala Thalody, et al.
Immunotherapy|December 17, 2019
Reinforcing the primary immunotherapy modulators against acute leukemia; monoclonal antibodies in AMLMehrdad Mahalleh, Mahsima Shabani, Elham Rayzan, et al.
Immunotherapy|November 5, 2020
Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignanciesNashwa El-Khazragy, Sherief Ghozy, Passant Emad, et al.
Immunotherapy|November 5, 2020
Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapyW Nathaniel Brennen, Daniel L J Thorek, Wen Jiang, et al.
Immunotherapy|January 18, 2018
CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapyGwendolyn J McGinnis, Jacob Raber
Immunotherapy|November 23, 2020
Current status and future development of anti-HIV chimeric antigen receptor T-cell therapyYunyu Mao, Chen Zhao, Peiyong Zheng, et al.
Immunotherapy|September 7, 2020
Potential clinical and serological predictors of chronic spontaneous urticaria relapse in patients under omalizumab treatmentTeresa Grieco, Laura Dies, Alvise Sernicola, et al.
Pageof 188